Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NBY
stocks logo

NBY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
3.00M
+22.9%
-0.210
-64.65%
Estimates Revision
The market is revising No Change the revenue expectations for NovaBay Pharmaceuticals, Inc. (NBY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -70.78%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-70.78%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY.A) is -1.27, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess NovaBay Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.08
Current PE
-1.27
Overvalued PE
-0.36
Undervalued PE
-3.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.46
Undervalued EV/EBITDA
-8.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.02
Current PS
0.00
Overvalued PS
2.68
Undervalued PS
-0.64
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NBY News & Events

Events Timeline

(ET)
2025-10-20
19:09:19
NovaBay Meets NYSE American Continued Listing Requirements Again
select
2025-08-26 (ET)
2025-08-26
16:11:38
NovaBay announces special cash dividend of 80 cents per share
select
2025-08-19 (ET)
2025-08-19
17:26:50
NovaBay Signs $6M Securities Purchase Agreement with David Lazar
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Benzinga
What Caused KALA BIO Shares to Surge More Than 22% After Market Close?

  • Stock Performance: KALA BIO, Inc. shares rose 22.16% to $1.13 in after-hours trading, despite being down 88% year-to-date, with a market cap of $7.59 million.

  • Oxford Finance Acquisition: Oxford Finance LLC acquired 1.62 million common shares, giving it a 16.5% ownership stake in KALA BIO, with sole voting power over the shares.

  • Leadership Change: David Lazar has been appointed as the new CEO and Principal Executive Officer of KALA BIO, previously serving as CEO of NovaBay Pharmaceuticals Inc.

  • Current Stock Trends: KALA stock has a negative price trend across all time frames, closing at $0.92, down 15.91% on the last trading day.

[object Object]
Preview
8.5
12-01Globenewswire
NioBay Metals Inc. Secures Up to C$5 Million for James Bay Niobium Project
  • Financing Plan: NioBay Metals Inc. has entered into an agreement with Red Cloud Securities to conduct a “best efforts” private placement aiming to raise up to C$5 million, which is intended to support the exploration and advancement of its James Bay Niobium Project.
  • Unit Pricing: Each unit is priced at C$0.14, with a minimum sale of 7,142,858 units to secure at least C$1 million in initial funding, thereby enhancing the company's financial stability.
  • Equity Structure: Each unit consists of one common share and one warrant, with a warrant exercise price of C$0.20, providing investors with potential future value appreciation and boosting market confidence.
  • Compliance and Regulation: The offering will comply with Canadian securities laws, ensuring sales in provinces such as Alberta, British Columbia, and Manitoba, thereby enhancing the company's transparency and credibility in the capital markets.
[object Object]
Preview
2.0
11-26Benzinga
What Caused KALA BIO's Almost 38% Overnight Increase?

  • Stock Performance: KALA BIO Inc. saw a significant increase of 37.87% in after-hours trading, reaching $0.88, following a regular session close at $0.64, despite a year-to-date decline of 91.72%.

  • Securities Purchase Agreement: The company entered a Securities Purchase Agreement to raise up to $6 million through a private placement, with the first closing raising $1.8 million from the sale of preferred shares.

  • Loan Settlement: KALA BIO reached a loan settlement with Oxford Finance LLC, involving a $2 million cash payment and the issuance of 1.62 million common stock shares, which will reduce the loan balance by $7 million.

  • New Leadership: David Lazar was appointed as the new CEO of KALA BIO, effective from the first closing of the securities agreement, having previously served as CEO of Novabay Pharmaceuticals Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NovaBay Pharmaceuticals Inc (NBY) stock price today?

The current price of NBY is 1.09 USD — it has increased 2.83 % in the last trading day.

arrow icon

What is NovaBay Pharmaceuticals Inc (NBY)'s business?

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

arrow icon

What is the price predicton of NBY Stock?

Wall Street analysts forecast NBY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBY is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NovaBay Pharmaceuticals Inc (NBY)'s revenue for the last quarter?

NovaBay Pharmaceuticals Inc revenue for the last quarter amounts to 521.00K USD, decreased % YoY.

arrow icon

What is NovaBay Pharmaceuticals Inc (NBY)'s earnings per share (EPS) for the last quarter?

NovaBay Pharmaceuticals Inc. EPS for the last quarter amounts to -0.22 USD, decreased -88.54 % YoY.

arrow icon

What changes have occurred in the market's expectations for NovaBay Pharmaceuticals Inc (NBY)'s fundamentals?

The market is revising No Change the revenue expectations for NovaBay Pharmaceuticals, Inc. (NBY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -70.78%.
arrow icon

How many employees does NovaBay Pharmaceuticals Inc (NBY). have?

NovaBay Pharmaceuticals Inc (NBY) has 14 emplpoyees as of December 05 2025.

arrow icon

What is NovaBay Pharmaceuticals Inc (NBY) market cap?

Today NBY has the market capitalization of 134.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free